Nouscom

Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom's proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators. Nouscom is currently advancing clinical development of its lead program, NOUS-209, an off-the-shelf cancer vaccine based on shared frameshift neoantigens. The Company continues to develop its product candidate, NOUS-PEV, a personalized cancer neoantigen vaccine, which is expected to enter clinical studies in 1Q 2021. Nouscom is led by an experienced management team with deep roots in the pharma and biotech industry (Merck, Novartis, Lilly, JNJ, Incyte and Okairos (acquired by GSK)), and are veterans in the field of viral vectored genetic vaccines. Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy , is backed by international life sciences investors: 5AM , Abingworth, LSP (Life Sciences Partners) and Versant Ventures.